case report aspiration glp-1 receptor agonist anesthesia 2023 Are patient factors associated with adverse perioperative outcomes in users? A retrospective cohort study Obesity drugs could fuel Count:30 HPLC Verified

case report aspiration glp-1 receptor agonist anesthesia 2023 Are patient factors associated with adverse perioperative outcomes in users? A retrospective cohort study Obesity drugs could fuel Count:30 HPLC Verified

Obesity drugs could fuel the next pharma CMO gold rush - Pharmaceutical Technology

Similarly, tirzepatide (Zepbound) demonstrated up to 22.5% weight loss in a 72-week trial with the same approach

HPLC Verified

Count:30

Data in weight loss Most of the existing empirical data on weight loss with GLP-1 agonists come from studies of individuals who are overweight or obese, with or without type 2 diabetes, rather than from studies using these agents to counteract iatrogenic weight gain